Increased nonesterified fatty acid (NEFA) levels may be important in causing insulin resistance in skeletal muscles in patients with non-insulin-dependent diabetes mellitus (NIDDM). The acute effect of the antilipolytic nicotinic acid analogue Acipimox (2 X 250 mg) on basal and insulin-stimulated (3 h, 40 mU/m2 per min) glucose metabolism was therefore studied in 12 patients with NIDDM. Whole-body glucose metabolism was assessed using 13-3Hjglucose and indirect calorimetry.
Introduction
Increased nonesterified fatty acid (NEFA) levels may be important in causing insulin resistance in skeletal muscles in patients with non-insulin-dependent diabetes mellitus (NIDDM). The acute effect of the antilipolytic nicotinic acid analogue Acipimox (2 X 250 mg) on basal and insulin-stimulated (3 h, 40 mU/m2 per min) glucose metabolism was therefore studied in 12 patients with NIDDM. Whole-body glucose metabolism was assessed using 13-3Hjglucose and indirect calorimetry.
Biopsies were taken from the vastus lateralis muscle during basal and insulin-stimulated steady-state periods. Acipimox reduced NEFA in the basal state and during insulin stimulation. Lipid oxidation was inhibited by Acipimox in all patients in the basal state (20±2 vs. 33±3 mg/m2 per min, P < 0.01) and during insulin infusion (8±2 vs. 17±2 mg/m2 per min, P < 0.01). Acipimox increased the insulin-stimulated glucose disposal rate (369±49 vs. 262±31 mg/m2 per min, P < 0.01), whereas the glucose disposal rate was unaffected by Acipimox in the basal state. Acipimox increased glucose oxidation in the basal state (76±4 vs. 50±4 mg/m2 per min, P < 0.01). During insulin infusion Acipimox increased both glucose oxidation (121±7 vs. 95±4 mg/m2 per min, P < 0.01) and nonoxidative glucose disposal (248±47 vs. 167±29 mg/m2 per min, P < 0.01). Acipimox enhanced basal and insulin-stimulated muscle fractional glycogen synthase activities (32±2 vs. 25±3%, P < 0.05, and 50±5 vs. 41±4%, P < 0.05). Activities of muscle pyruvate dehydrogenase and phosphofructokinase were unaffected by Acipimox. In conclusion, Acipimox acutely improved insulin action in patients with NIDDM by increasing both glucose oxidation and nonoxidative glucose disposal. This supports the hypothesis that elevated NEFA concentrations may be important for the insulin resistance in NIDDM. The mechanism responsible for the increased insulin-stimulated nonoxidative glucose disposal may be a stimulatory effect of Acipimox on glycogen synthase activity in skeletal muscles. (J. Clin. Invest. 1991.88:1282-1290.) Key words: glucose-fatty acid cycle * glycogen synthase * insulin resistance* phosphofructokinasepyruvate dehydrogenase
Patients with non-insulin-dependent diabetes mellitus (NIDDM)l are characterized by resistance to insulin-stimulated glucose uptake in peripheral tissues (predominantly skeletal muscles), and it is generally believed that this defect plays an important role in the pathogenesis of the syndrome. Patients with NIDDM often have elevated fasting and postprandial concentrations of nonesterified fatty acids (NEFA) in plasma (1, 2) . This may be due to an increased rate of lipolysis in adipose tissues and skeletal muscles in patients with NIDDM. A significant direct correlation between degree of plasma NEFA concentration and magnitude of fasting hyperglycemia has been documented in patients with NIDDM (3, 4) . Furthermore, elevations in plasma NEFA concentration have been shown to lower insulin-stimulated glucose uptake in normal individuals (5, 6) . Thus, it has been hypothesized that insulin resistance in patients with NIDDM may be caused by or may be partly due to elevated NEFA concentrations in plasma and skeletal muscles. Recently, this hypothesis has been furtherdocumented by Reaven et al. (7), who demonstrated a lowering effect ofplasma glucose in streptozotocin-induced diabetic rats by two different antilipolytic agents, nicotinic acid (NA) and phenylisopropyladenosine (7) . NA was shown to increase in vivo insulin-stimulated glucose uptake in peripheral tissues, and both NA and PIA were shown to increase in vitro insulinstimulated glucose uptake in isolated adipocytes.
The mechanisms that control the relationship between fatty acid and glucose utilization in human skeletal muscle are not clear. The classic glucose-fatty acid cycle, demonstrated by Randle et al. (8) in isolated rat hearts and hemidiaphragms, involves an inhibitory effect of NEFA on glycolysis and pyruvate oxidation. In this model, no effect of NEFA on glycogen synthesis was demonstrated. The inhibitory effect ofNEFA on glycolysis and glucose oxidation was explained by the same group to be caused by a buildup of mitochondrial citrate and acetyl-coenzyme A (CoA), and a rise in the cytoplasmic NADH/NAD ratio (9, 10) . The increase in acetyl CoA/CoA ratio activates pyruvate dehydrogenase kinase (11, 12) , which then phosphorylates and inactivates the pyruvate dehydrogenase (PDH) complex. Accumulation ofcitrate causes an inhibition ofphosphofructokinase (PFK) (13) , thus slowing down the 1. Abbreviations used in this paper: F-6-P and F-6,1-dP, fructose 6-phosphate and fructose 1,6-diphosphate; G-6-P, glucose 6-phosphate; GS, glycogen synthase; HGP, hepatic glucose production; NA, nicotinic acid; NEFA, nonesterified fatty acid(s); NIDDM, non-insulin-dependent diabetes mellitus; PDH, PDHa, and PDHt, pyruvate dehydrogenase, active PDH, and total PDH; PFK, phosphofructokinase; glycolytic flux. This may cause an accumulation of glucose-6-phosphate (G-6-P), which again inhibits the activity of hexokinase in turn causing an intracellular accumulation of free glucose that decreases the gradient of glucose across the cell membrane. These mechanisms, however, have never been demonstrated to operate in human skeletal muscles.
Acipimox (5-methyl-pyrazine carboxylic acid 4-oxide, Farmitalia Carlo Erba, Milano, Italy) is a new potent and long-acting (8 h) antilipolytic drug, which has been derived from NA (14) . By lowering plasma and possibly skeletal muscle concentrations of NEFA, Acipimox may have a potential beneficial effect on glucose metabolism in patients with NIDDM. Furthermore, besides being more long acting, Acipimox may have the potential advantage over nicotinic acid that it causes a minor "rebound" effect on lipolysis (15) . The aim of this study was to evaluate the acute effect of Acipimox on basal and insulinstimulated whole-body glucose metabolism in patients with NIDDM. Furthermore, by taking biopsies from skeletal muscles, we intended to establish whether changes in key enzyme activities in this tissue could be responsible for any of the in vivo effects of Acipimox. Thus, by using Acipimox, we intended to study the importance of and the possible mechanisms behind the glucose-fatty acid cycle in human subjects with NIDDM.
Methods

Subjects
12 patients with NIDDM were included in the study. Their characteristics are given in Table I . The patients were obese and most of the subjects (n = 7) had fasting plasma triglyceride concentrations above the upper normal limit (2.20 mmol/liter). Five patients were treated with diet alone and seven patients were treated with diet and oral hypoglycemic drugs (sulfonylurea or metformin). During the study period, patients were on a weight-maintaining diet consisting of -55% carbohydrate, 15% protein, and 30% fat. Oral hypoglycemic drugs were withdrawn at least 36 h before each metabolic study. Five proliferative retinopathy. Patients were informed ofthe nature and the purpose of the study before their voluntary consent to participate was obtained. The study was approved by the regional ethical committee and the procedure was performed according to the principles of the Helsinki Declaration.
Study design
The study was designed as a double-blind crossover study. An isoglycemic insulin clamp (40 mU/m2 per min) was performed on two separate days in random order (Fig. 1) . The second study in each patient was carried out 4-6 wk apart from the first study. On one day patients received Acipimox (2 X 250 mg) and on the other day they received placebo. Acipimox or placebo tablets were given 150 min before the basal steady state period and 150 min before the insulin-stimulated steady-state period. The studies were carried out in combination with indirect calorimetry and infusions of [3-3H] glucose to allow quantification of respiratory gas exchange, total glucose turnover, and hepatic glucose production (HGP). On both study days, muscle biopsies were performed from the vastus lateralis muscle after the basal steady-state period and after the insulin-stimulated steady state period (Fig. 1) .
In vivo methods Figure 1 . Experimental study design. Plasma glucose was clamped at the fasting glucose concentration during insulin infusion (isoglycemic clamp procedure). Each isoglycemic clamp study was preceded by a 120-min period for basal measurements (darkened bars). Insulin was infused for 180 min at a rate of 40 mU/m2 per min. Steady-state measurements of glucose turnover were made, and indirect calorimetry was carried out during last 30 min of basal and clamp periods. During this time, blood was analyzed for insulin, C-peptide, triglycerides, NEFA and lactate every 10 min. Muscle biopsies were taken from the vastus lateralis muscle in the basal state and after 180 min of insulin infusion. Each subject was studied twice in randomized order with or without 2 x 250 mg of Acipimox.
ing an infrared carbon dioxide sensor. Signals from the gas analyzers are processed by the computer and oxygen consumption and carbon dioxide production are calculated and recorded once per minute. After an equilibration period of 10 min, the average gas exchange rates recorded over the two 30-min steady-state periods ( Fig. 1 ) were used to calculate rates ofglucose oxidation, lipid oxidation, and energy expenditure as previously described (19, 20) . The CO2 concentrations did not exceed 1% at any time point during the steady-state measurements. The protein oxidation rate was estimated from urinary urea nitrogen excretion (1 g ofnitrogen = 6.25 g ofprotein) and corrected for changes in pool size (21) . Muscle biopsy. Muscle biopsies were performed with a modified Bergstrom needle (including suction) under local anesthesia. The biopsies were rapidly (within 10-15 s) frozen in liquid nitrogen, where they were stored for later analysis. Before the biochemical analysis was performed, samples were freeze-dried and dissected free ofvisible connective tissue, fat, and blood.
Calculations. During the steady-state periods, glucose turnover rates (HGP and total peripheral glucose uptake) were calculated at 10-min intervals using Steele's non-steady-state equations (22) . Nonsteady-state equations were used during basal measurements because ofspontaneous declining plasma glucose concentrations on both study days in most patients. In these calculations, the distribution volume of glucose was taken as 200 ml/kg body weight and the pool fraction as 0.65 (23) . Negative rates of HGP were calculated in most patients during insulin-stimulated steady-state periods. Such underestimation of glucose turnover by the tracer method is largely accounted for by a model error emerging at high rates of glucose metabolism (24) . We took the negative numbers to indicate a nil HGP. Because HGP was fully suppressed during insulin infusion, the infusion rates of exogenous glucose (molar values) were equal to total peripheral glucose uptake. Total peripheral glucose uptake was corrected for urinary glucose excretion. Nonoxidative glucose metabolism was calculated as the difference between total body glucose uptake and glucose oxidation, as determined by indirect calorimetry.
In vitro methods
Glycogen and metabolite concentrations in muscle biopsies. Glycogen was measured as glucose residues after hydrolysis of the muscle samples, in 1 M HCI at 100IC for 2 h (25). Glucose, G-6-P, and lactate were measured fluorometrically on neutralized perchloric acid extracts (25) . The intracellular concentrations of free glucose, G-6-P, and lactate were calculated as millimoles per liter intracellular water, assuming an extracellular water content in the biopsies of0.3 liter/kg dry weight and an intracellular water content of 2.8 liter/kg dry weight (26, 27) . Intracellular concentrations of free glucose and lactate were corrected for extracellular concentrations using the above assumptions ofintracellular and extracellular water content in the biopsies.
Muscle enzyme activities. Extraction of muscle samples and assays for glycogen synthase (GS), PDH, and PFK activities were performed as previously described by Mandarino et al. (28) .
PDH assays were performed by a modification of the method of Hagg et al. (29) , based on the technique ofBlass et al. (30) . Briefly, PDH activity was determined in the presence of low (50 uM) and high (10 mM) magnesium concentrations to determine active (PDHa) and total (PDHt) enzyme activity. PDH activity was expressed as picomoles of pyruvate oxidized per minute per milligram extract protein. The fractional activity ofPDH is defined as the proportion oftotal enzyme that is active (PDHa/PDHt). This measure has been used as a measure of the extent of activation of PDH in vivo (31) .
GS was assayed by a modification of the method of Thomas et al. (32) . GS activity was assayed in the presence of a near-physiological concentration of(0.1 mM) and in the presence ofa high concentration of G-6-P (10 mM) to determine maximal enzyme activity. The total concentration of uridine diphosphate glucose ([(4C]UDPG + cold UDPG) in the reaction mixture was 0.31 mM. GS activity was expressed as nanomoles ofUDPG incorporated into glycogen per minute per milligram extract protein. Fractional velocity that is thought to reflect the proportion of total GS present that is active in vivo was calculated as the ratio between GS activity assayed at 0.1 mM G-6-P and 10 mM G-6-P.
PFK activity was assayed spectrophotometrically in supernatants of muscle extracts by a modification of the method of Beutler (33) . The assay coupled the conversion of fructose 6-phosphate (F-6-P) to fructose 1,6-diphosphate (F-1,6-dP) with the oxidation ofNADH by means of a series of enzymatic steps including aldolase, triose phosphate isomerase, and a-glycerolphosphate dehydrogenase. Activity of PFK was assayed in the presence of a near-physiological concentration of F-6-P (0.1 mM) and in the presence of a high concentration of F-6-P (2.0 mM) to determine the maximal activity of the enzyme. PFK activity was expressed as nanomoles ofF-6-P converted to F-1,6-dP per minute per milligram extract protein.
Protein content of the extracts was determined by the method of Lowry et al. (34) .
Analytical determinations. Glucose in plasma and urine was determined by a hexokinase method (35) . Tritiated glucose activity was measured as previously described (18, 36) . Plasma insulin (37) and C-peptide (38) 
Results
Plasma glucose, insulin, and C-peptide concentrations are given in Table II . Plasma glucose concentrations were similar on the two study days. A spontaneous decline in plasma glucose concentration was observed during the basal period (0-120 mmn) on both study days. Although the decline was slightly higher on the day where patients received Acipimox, this difference was not statistically significant. Plasma insulin and C-peptide concentrations were the same on both study days during both steady-state periods. Plasma concentrations ofinsulin and C-peptide were constant during the predefined basal and insulin stimulated steady-state periods, indicating that steady state was achieved during these two intervals. The mean coefficients of variation of plasma glucose concentrations during insulin infusion were 3% during placebo studies and 2% Acipimox studies. Acipimox significantly lowered plasma concentrations of triglycerides and NEFA during the basal steady-state period and during the insulin-stimulated steady-state period (Table  III) . The mean coefficient of variation of plasma NEFA concentrations during insulin infusion was 12% during placebo studies and 15% during Acipimox studies. Acipimox increased plasma concentrations of lactate during both steady-state periods.
The CO2 concentrations under the hood during indirect calorimetry measurements remained constant and did not exceed 1% at any time point during the steady-state periods. Lipid oxidation (Fig. 2) Fig. 2 ). During insulin infusion, however, Acipimox increased total peripheral glucose uptake in all patients (369±49 vs. 262±31 mg/m2 per min, P < 0.01, Fig. 2 ).
Owing to an increased glucose oxidation and an unaffected total peripheral glucose uptake, Acipimox significantly inhibited nonoxidative glucose metabolism in the basal state (21±5 vs. 44±5 mg/M2 per min, P < 0.02, Fig. 2) . During insulin infusion, however, Acipimox had a marked stimulatory effect on nonoxidative glucose metabolism (248±47 vs. 167±29 mg/ m2 per min, P < 0.01, Fig. 2) . No correlation was found between the inhibitory effect of Acipimox on lipid oxidation and the stimulatory effect of Acipimox on nonoxidative glucose disposal during insulin infusion (r = 0.07, NS).
HGP was unaffected by Acipimox in the basal state (placebo vs. Acipimox, 86±2 vs. 91±3 mg/m2 per min, NS) and was completely suppressed by insulin on both the day where patients received placebo (-72±17 mg/m2 per min) and Acipimox (-74±31 mg/m2 per min). Acipimox increased the activity of glycogen synthase (FV0, ) in biopsies from skeletal muscles in the basal state and during insulin infusion (Table IV) . Furthermore, the physiological insulin stimulation in the present study (40 mU/m2 per min) was able to increase the activity of glycogen synthase (FV0.1) on both study days. No effect of Acipimox or insulin was seen on total GS activity. Insulin activated PDHa, whereas PDHt was unaffected by insulin (Table IV) . Thus, the PDH activity ratio PDHa/PDHt increased during the insulin infusion. Surprisingly, no effect of Acipimox was seen on the activity ofPDHa or PDHt. Furthermore, no effect of Acipimox was seen on the activity of PFK either in the basal state or during insulin infusion (Table IV) . Insulin had no effect on the activity of PFK.
Intracellular concentrations of free glucose, G-6-P, glycogen, and lactate in skeletal muscles are given in Table V . Acipimox or insulin had no effect on intracellular concentrations of (19) . This means that an increase in de novo lipogenesis in the liver or adipose tissue, unaccompanied by changes in lipid or glucose oxidation, could be misinterpreted as a decrease in the rate of lipid oxidation and/or an increase in the rate ofglucose oxidation. Therefore, it could be claimed that the effects of Acipimox on lipid and glucose oxidation in the present study partly could be due to a stimulatory effect of Acipimox on de novo fatty acid synthesis. We are, however, unaware of any data indicating that Acipimox may increase de novo lipogenesis. Furthermore, preliminary in vitro experiments on isolated present study.
In vivo studies in humans have demonstrated that infusion of intralipid (a triglyceride emulsion) with heparin during different degrees ofinsulinization causes increased lipid oxidation and decreased glucose oxidation in normal subjects (5) and in patients with NIDDM (43) . The present in vivo data demonstrates that the glucose-fatty acid cycle also operates the other way round in patients with NIDDM. The tissue, however, which is responsible for the in vivo effects of Acipimox on glucose oxidation, remains obscure. If a true inverse Randle's cycle in skeletal muscles was responsible for the in vivo effects of Acipimox on glucose oxidation in the present study, one would have expected increased activities of PDH and PFK in biopsies from skeletal muscles. Furthermore, decreased intracellular concentrations of free glucose and G-6-P in skeletal muscles would have been expected. No effect of Acipimox on any ofthese enzyme activities or substrate concentrations were detected in the basal state or during insulin infusion in this study, suggesting that the in vivo effect ofAcipimox on glucose oxidation was not due to an increased oxidation of glucose in skeletal muscles. The fact that the effect of Acipimox on glucose oxidation was seen in both the basal state and during insulin infusion, and furthermore, that the stimulatory effect of Acipimox on glucose oxidation was exactly the same in both situations (26 mg/m2 per min) demonstrates that this effect is independent of the degree of insulinization. This could be taken as an indirect evidence for that the effect ofAcipimox on whole-body glucose oxidation may not necessarily be located to an insulin-sensitive tissue. This is consistent with data from animal studies that the glucose-fatty acid cycle operates in nonmuscle tissue such as kidney and liver (44) . We did, however, find a significant stimulation ofthe PDH activity during insulin infusion on both study days. This may suggest that the increase in whole-body glucose oxidation seen on both study days during insulin infusion could be due to an increase in glucose oxidation in skeletal muscles.
An alternative explanation for the lack of effect of Acipimox on PDH and PFK activities, and on concentrations offree glucose and G-6-P, could be that the mechanisms regulating glucose oxidation in human skeletal muscles are different from the mechanisms which were pointed out by Randle and coworkers on perfused rat hearts and hemidiaphragms. It is important to emphasize that the regulatory mechanisms suggested by Randle have never been demonstrated to operate in human skeletal muscles. In addition, several investigations have failed to show inhibitory effects ofNEFA on glucose utilization in various animal skeletal muscle preparations (45) (46) (47) (48) (49) (50) .
An alternative mechanism, by which Acipimox may stimulate glucose oxidation in human skeletal muscle could be through a direct stimulation of glucose transport over the cell membrane. An increased glucose transport over the cell membrane may enhance the flux through glycolysis and the citric acid cycle, thus increasing glucose oxidation. If this was the mechanism, enzyme activities and substrate concentrations in biopsies from skeletal muscles could be unaffected by Acipimox despite an increased glucose oxidation in the tissue. In fact, NA has been shown to increase glucose transport into rat adipocytes under in vitro experimental conditions (51) . We found that Acipimox increased peripheral glucose uptake during insulin infusion, but not in the basal state. Thus, an increased glucose transport into the muscle cell could explain the increase in glucose oxidation during insulin infusion, but not in the basal state. The increase in glucose oxidation, however, was exactly the same in the basal state and during insulin infusion, suggesting identical stimulatory mechanisms in the two states. Therefore, an increased glucose transport over the muscle cell membrane is unlikely to be the explanation for the increase in glucose oxidation caused by Acipimox.
The key point in the Randle's cycle is PDH. This enzyme exists in a phosphorylated less active and a dephosphorylated more active form. The fractional activity of PDH (PDHa/ PDHt) is decreased by starvation or induction of alloxan-diabetes (insulin deficient diabetes) in rat heart, rat skeletal muscle, rat liver, rat kidney, and rat adipose tissue (52) (53) (54) (55) (56) . Randle suggested that the decreased fractional activity ofPDH in skeletal muscles could explain the impaired glucose metabolism in diabetes. This hypothesis was, however, based on data obtained in an insulinopenic model, which in humans resembles insulin-dependent diabetes (IDDM) more than it resembles the hyperinsulinemic syndrome NIDDM. Recently, it was demonstrated by Kelley and Mandarino (57) that PDH activity in skeletal muscles from patients with NIDDM is not decreased compared to normal subjects. Instead, these authors demonstrated an increased skeletal muscle PDH activity during fasting hyperglycemia in patients with NIDDM. The fact that PDH may not be defective in NIDDM may also provide an explanation for the lack ofeffect ofAcipimox on PDH activity. Thus, it has been shown that intravenous administration ofthe fatty acid oxidation inhibitor 2-tetradecylglycidic acid had no effect on the proportion of PDH complex in the active form in heart, diaphragm or gastrocnemius muscles or in liver, kidney, or adipose tissue of fed normal rats (58) . However, the fatty acid oxidation inhibitor was able to reverse effects ofstarvation and alloxan-diabetes on the proportion ofactive PDH complex in heart muscle.
Acipimox had no effect on peripheral glucose uptake in the basal state, whereas during insulin infusion Acipimox had a marked stimulatory effect on peripheral glucose uptake. In other words, Acipimox improved insulin action in the NIDDM patients. The quantitatively most important part of this effect was on the insulin-stimulated nonoxidative glucose uptake. Under insulin-stimulated conditions, nonoxidative glucose metabolism is thought to primarily represent muscle glycogen synthesis (59) and is correlated with the activity of skeletal muscle GS in normal subjects and in patients with NIDDM (28, 59, 60) . We found that Acipimox increased the activity of GS in skeletal muscles in the basal state and during insulin infusion. Thus, during insulin infusion, the increased activity of GS in skeletal muscles may be responsible for the increased whole-body nonoxidative glucose metabolism. In the basal state, however, we found an increase in muscle GS activity, which was not reflected by an increase in whole-body nonoxidative glucose disposal. In contrast, we found a slight decrease in nonoxidative glucose uptake in the basal state. This apparently paradoxical phenomenon may be explained by the fact that, in the basal postabsorptive state, skeletal muscle is responsible for only a small part (< 20%) ofthe total peripheral glucose uptake (61) . In contrast, skeletal muscle is responsible for the majority ofperipheral glucose uptake during high physiological insulin concentrations (61) . Thus, in the basal state whole body nonoxidative glucose uptake may represent other biochemical pathways than glycogen synthesis in skeletal muscles. Such pathways could be either lipogenesis or the pentose phosphate shunt in the liver or in adipose tissue.
Lactate formation from glycolysis is a further nonoxidative pathway, which operates in most tissues. Acipimox slightly increased plasma concentrations of lactate in the basal state and during insulin infusion. Thus, increased lactate formation may also be responsible for the increased nonoxidative glucose metabolism during insulin infusion. Because intracellular muscle lactate concentrations were unaffected (or slightly decreased) by Acipimox, however, the increased plasma lactate concentration is not likely to be due to increased lactate formation in skeletal muscles. Furthermore, the possibility that the increased plasma lactate concentration during Acipimox studies could be due to an impaired uptake oflactate in liver or muscle cannot be excluded from the present data.
An important question is now whether the increase in nonoxidative glucose metabolism and GS activity was caused by a lower tissue availability of free fatty acids, or whether this was an effect ofthe drug per se. This question may be important not only for the understanding of the pharmacological action of Acipimox, but also for the understanding ofthe impaired insulin action in NIDDM. This is further illustrated by the fact that the impaired insulin-stimulated nonoxidative glucose disposal may be of primary (i.e., genetic) origin in NIDDM (62) . The influence of free fatty acids on nonoxidative glucose metabolism is controversial. Infusion of intralipid with heparin has been shown to inhibit nonoxidative glucose metabolism in normal subjects (5) . In obese subjects (63) and in patients with NIDDM (44), however, infusion of intralipid did not inhibit nonoxidative glucose disposal. In the present study, no correlation between the effect of Acipimox on lipid oxidation and nonoxidative glucose disposal was demonstrated. This suggests that a pure effect of a lower NEFA availability may not solely explain the effect of Acipimox on nonoxidative glucose disposal. Furthermore, Randle and co-workers did not demonstrate any inhibitory effect of NEFA on glycogen synthesis on the perfused rat hearts and hemidiaphragms. This is in contrast to a very recent publication, where elevated concentrations of NEFA were shown to inhibit glycogen synthesis in an in vitro human muscle strip preparation (64) . Acipimox inhibits lipolysis in adipose tissue by lowering intracellular concentrations of cyclic AMP (65) . If this is also the case in skeletal muscles, Acipimox may decrease the activity of the cyclic AMP-dependent protein kinase by this mechanism. This may cause an increase in GS activity due to an increased proportion of GS being on the more active dephosphorylated form. Thus, it is presently unclear whether the effect of Acipimox on GS activity is direct or indirect elicited by changes in NEFA.
In previous studies, nicotinic acid has been shown to both increase and decrease plasma glucose concentration in normal and diabetic humans and animals (7, (66) (67) (68) (69) (70) (71) (72) (73) (74) . The reason for these discrepancies is not clear. The most obvious explanation for this is the rebound in plasma NEFA levels noted to occur with chronic administration of NA. Thus, most acute experiments with NA have found a beneficial effect on glucose metabolism, while most chronic experiments have revealed a deterioration (diabetogenic effect) on glucose metabolism. Other explanations for the different effects of NA on glucose metabolism in different studies could be species differences or a question of doses. However, if the problem lies in the rebound effect in plasma NEFA levels, Acipimox may also have potential beneficial effects on glucose metabolism in NIDDM patients with chronic treatment, owing to the less tendency to cause this rebound effect (15) . A long-term study is required to answer this question.
In conclusion, acute inhibition of lipolysis with Acipimox improved insulin action in patients with NIDDM by increasing both insulin-stimulated glucose oxidation and nonoxidative glucose disposal. This supports the hypothesis that elevated NEFA levels may be important for the development of insulin resistance in NIDDM. The increase in nonoxidative glucose disposal was the quantitatively most important and was probably caused by an increased activity of GS in skeletal muscles. The increase in glucose oxidation was seen both in the basal state and during insulin infusion and could not be attributed to increased activities of PDH and/or PFK in skeletal muscles. This suggests that nonmuscle tissues may be responsible for the increase in glucose oxidation caused by Acipimox. A long-term study with Acipimox is required to demonstrate whether the acute beneficial effect on glucose metabolism can also lead to a long-term improvement of metabolic control in NIDDM patients.
